News for Gilead Sciences, Inc. (GILD)

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD. And retail traders should know. We noticed this today when the tra...

Gilead Sciences and Johnson & Johnson are part of the Zacks Investment Ideas article.

Here is how Gilead Sciences (GILD) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

**media[561032]**

Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.

Financial markets volatile since Trump's 2024 election, some companies surged like Palantir while others struggled such as First Solar.

In the current session, the stock is trading at $116.29, after a 0.22% spike. Over the past month, Gilead Sciences Inc. GILD stock increased by 21.08%, and in t...

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Gilead Sciences, Inc. (NASDAQ:GILD) TD Cowen 45th Annual Healthcare Conference March 4, 2025 11:10 AM ETCompany ParticipantsJohanna Mercier - Chief...

SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( NRIX), a clinical-stage biopharmaceutical company focused on the discovery, devel

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $115.99, denoting a +1.47% change from the preceding trading day.

**media[555300]**

**media[552869]**

Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

**media[552077]**

”“ Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 ”“ ”“ Biomarker of

Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors have been highlighted in this Screen of The Week article.

Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corporation (SCHW), Gilead Sciences, Inc. (GILD) and Medtronic plc (MDT), as well as two micro-cap stocks Cooper-Standard Holdings Inc. (CPS) and Rave Restaurant Group, Inc. (RAVE).

Gilead Sciences Inc (GILD) announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) and EU-M4all applicati